Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
May 31, 2025
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
Conditions
Head and Neck Cancer Squamous Cell Carcinoma
Interventions
DRUG
VS-101
VS-101
DRUG
Cisplatin
Cisplatin
RADIATION
Radiation
Radiation
All Listed Sponsors
lead
VSPharmTech Co.,Ltd.
INDUSTRY
NCT06959082 - Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer | Biotech Hunter | Biotech Hunter